Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer

This study has been completed.

Sponsor:

Collaborator:

GlaxoSmithKline

Information provided by (Responsible Party):

Sarah Cannon Research Institute

ClinicalTrials.gov Identifier:

NCT00294190

First received: February 16, 2006

Last updated: December 6, 2012

Last verified: May 2011

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	July 2009
Primary Completion Date:	September 2007 (Final data collection date for primary outcome measure)

No publications provided by Sarah Cannon Research Institute

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Spigel DR, Greco FA, Burris HA 3rd, Shipley DL, Clark BL, Whorf RC, Arrowsmith ER, Hainsworth JD. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer. Clin Lung Cancer. 2011 May;12(3):187-91. Epub 2011 Apr 28.

To Top